Skip to Content

Iclusig Approval History

Iclusig (ponatinib) is a kinase inhibitor for the treatment of chronic myeloid leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL).

Development History and FDA Approval Process for Iclusig

Dec 14, 2012Approval FDA Approves Iclusig to Treat Two Rare Types of Leukemia
Oct 24, 2012ARIAD Announces U.S. Food and Drug Administration Acceptance of NDA Filing for Ponatinib
Aug 13, 2012Ariad Announces Submission of New Drug Application for Ponatinib to the U.S. Food and Drug Administration

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.